Plain-English translation of NCT06660524 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether a medication called can slow down the calcification (hardening) of heart valves in people who have both chronic kidney disease and degenerative heart valve disease. Researchers will compare to a more traditional treatment called to see which one works better at preventing valve calcification over one year.
People with kidney disease often develop problems with calcium and phosphorus balance in their blood, which can lead to heart valve hardening. This trial is testing whether the medication can help protect the heart valves and reduce serious heart complications in this group of patients.
You likely qualify if…
You likely don't qualify if…
You would take either or as a daily oral medication for 12 months. You would have heart imaging scans (echocardiography and CT) at the start and after 12 months to measure any changes in valve calcification. You would attend follow-up visits at 3, 6, 9, and 12 months for blood work and to check how you're responding to treatment.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China